Dutch drug maker Novo Nordisk A/S (NVO) posted higher first-quarter net profit of 5.98 billion Danish kroner, or 10.98 Danish kroner a share, compared with 4.66 billion Danish kroner, or 8.32 Danish kroner a share a year before. Quarterly operating profit rose by 18% to 7.56 billion Danish kroner, from the prior year's 6.39 billion Danish kroner, and was up 21% on a local currencies basis.
Three-month sales advanced by 13% year-over-year to 19.98 billion Danish kroner, from 17.75 billion Danish kroner, driven by Victoza, NovoRapid and Levemir. In local currencies, sales went up 14%.
For 2013, sales growth, in local currencies, is now expected to be 9-11%, versus its prior range of 8-11%, whereas operating profit growth measured in local currencies is still expected to be around 10%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.